Physician profile
Htun Latt
NPI 1679990527
$4,500.75
in general payments reported to CMS, 2019-2025
19 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $726 · 2021: $1,422 · 2022: $498 · 2023: $382 · 2024: $343 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $724.71 | 2020-2024 | Diamondback Coronary, Diamondback Peripheral |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $718.95 | 2019-2021 | |
| Medtronic, INC. | $551.07 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $510.27 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $484.46 | 2022-2024 | |
| Boston Scientific Corporation | $317.72 | 2020-2021 | |
| Shockwave Medical, INC | $224.31 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| W. L. Gore & Associates, INC. | $219.19 | 2019-2021 | |
| Cardiovascular Systems INC. | $198.22 | 2019-2022 | |
| Amgen INC. | $139.25 | 2023-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $95.73 | 2019 | |
| Abiomed | $86.11 | 2021 | |
| Janssen Pharmaceuticals, INC | $68.67 | 2019-2022 | |
| Pfizer INC. | $39.23 | 2023-2024 | |
| Terumo Medical Corporation | $32.02 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25.16 | 2020-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $24.89 | 2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.09 | 2024 | Jardiance |
| Astellas Pharma US INC | $17.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Htun Latt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.